NCT07592988Completed
Tear Interleukin Biomarkers After Glaucoma Treatment
Tear Fluid Interleukin Biomarkers and Intraocular Pressure Response After Micropulse Transscleral Cyclophotocoagulation, Conventional Cyclophotocoagulation, and Antiglaucoma Surgery in Patients With Glaucoma
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
This prospective study aims to evaluate inflammatory biomarkers in tear fluid in patients with glaucoma undergoing micropulse transscleral cyclophotocoagulation (MP-CPC), continuous-wave cyclophotocoagulation (CPC), and antiglaucoma surgeries. The study will assess the concentrations of pro- and anti-inflammatory interleukins in tear samples collected before treatment, 5-7 days after the procedure, and 1 month postoperatively. Intraocular pressure (IOP) will be measured at the same time points. The correlation between changes in interleukin levels and IOP reduction will be analyzed. Additionally, the study aims to compare inflammatory response patterns among the MP-CPC, CPC, and surgical treatment groups and to identify interleukin profiles associated with a clinically significant hypotensive effect.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 24 (actual)
- First submitted
- 12 May 2026
- Start date
- 18 May 2026
- Primary completion date
- 18 Aug 2026
- Lead sponsor
- Kazakh Eye Research Institute
- Diseases
- Glaucoma
- NCT number
- NCT07592988
What you commit to
- Study type: Interventional
- Participants enrolled: 24
- From 18 May 2026 to the primary completion date, 18 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with ocular infection, inflammation or intraocular surgery in the study eye 2 months prior to enrollment in the study
Age
- Patients age less than 18 years
Other
- Patients unable or unwilling to provide informed consent to participate in the study
- Patients potentially unavailable for follow up visits
- Patients with significant scleral thinning
- Albino patients that have no iris pigmentation
Who the study is looking for
- Decision to treat by MP-CPC Laser
- Patients diagnosed with Glaucoma
- Patients aged 18 years old and above
- Glaucoma that is inadequately controlled on medical therapy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kazakh Eye Research Institute Coordinator of this site? Confirm its status | Almaty | Kazakhstan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.